Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Amgen Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Gilead Sciences Inc
Kurome Therapeutics Inc
Kymera Therapeutics LLC
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
AS-2444697 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1834845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986126 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-4948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-5718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Discontinued Products
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Aurigene Discovery Technologies Ltd, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Genentech Inc, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Kurome Therapeutics Inc, H1 2020
Pipeline by Kymera Therapeutics LLC, H1 2020
Pipeline by Nyrada Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Rigel Pharmaceuticals Inc, H1 2020
Pipeline by TG Therapeutics Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020